Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2007

View Archived Issues

Genzyme rounds up recent pipeline developments

New treatment options for hepatitis C described in recent patents

Novel analgesic agents imparted in recent Merck patent

AM-101 begins phase I/II study for tinnitus

Enrollment closes in phase II Bronchitol study in cystic fibrosis

Kuros' solitary bone cyst product awarded U.S. orphan drug status

Celebrex label extended to include ankylosing spondylitis in E.U.

Chimerix closes Series D financing

Pro-Pharmaceuticals to discuss Davanat NDA with FDA

GS-9137 completes phase II study in HIV

Devgen awarded grant to support obesity program

NovoSeven reduces intracerebral bleeding, fails to improve long-term outcomes

New therapeutic agents for neurological disorders reported in recent patents

Zonisamide efficacy unclear in essential tremor study

Hyaluronic acid dermal filler injections stimulate collagen synthesis

ASCENT results support evaluation of calcitriol/docetaxel in prostate cancer

Virus-like particle seasonal influenza vaccine induces broad immune responses in vivo

VMP-001: a novel highly immunogenic vaccine against Plasmodium vivax

Prolactin promotes CNS remyelination and repair upon neuronal demyelination

Elan reflects on Q4 progress

Cymbalta approved for generalized anxiety disorder

FK-506 Modified Release recommended for approval in Europe

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...